HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

CHOP followed by involved field radiotherapy for localized primary gastric diffuse large B-cell lymphoma: results of a multi center phase II study and quality of life evaluation.

Abstract
We aimed to define the role of cyclophosphamide, vincristine, doxorubicin, prednisone (CHOP) followed by involved field radiotherapy (IFRT) for treating localized primary gastric diffuse large B-cell lymphoma (DLBCL). Newly diagnosed patients with localized primary gastric DLBCL were to receive four cycles of CHOP followed by IFRT of 40.0 Gy. At 1 year after the completion of treatment, patients filled out the EORTC Quality of Life Questionnaire specified for stomach cancer (QLQ-C30-STO22). Fifty evaluable patients (25 men, 25 women) were included. The median age was 54.5 years (range, 21 - 73 years. The overall response rate to the CHOP was 94% (95% confidence interval [CI], 87 - 100) in the intent-to-treat population. Forty-one of the 50 patients (82%; 95% CI, 71 - 93) achieved complete remission (CR). After the completion of radiotherapy, five patients who were in PR following chemotherapy eventually attained CR. The overall complete response rate was thus 92% (95% confidence interval, 84 - 99). With a median follow-up period of 30 months, the 2-year progression-free and overall survival rate was 92% and 92%, respectively. The gastric function was well preserved with negligible stomach-related symptoms at 1 year after the completion of treatment. This organ-preserving combined treatment is highly effective and well tolerated for the patients with localized gastric DLBCL.
AuthorsYeon Hee Park, Se-Hoon Lee, Won Seog Kim, Soo-Mee Bang, Baek-Yeol Ryoo, Sung Hyun Yang, Seung-Sook Lee, Mi Sook Kim, Kihyun Kim, Keon Woo Park, Do Hyoung Im, Jung Hun Kang, Jeeyun Lee, Young H Ko, Yong Chan Ahn, Do Hoon Lim, Keunchil Park
JournalLeukemia & lymphoma (Leuk Lymphoma) Vol. 47 Issue 7 Pg. 1253-9 (Jul 2006) ISSN: 1042-8194 [Print] United States
PMID16923554 (Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study)
Chemical References
  • Antineoplastic Agents
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone
Topics
  • Adult
  • Aged
  • Antineoplastic Agents (pharmacology)
  • Antineoplastic Combined Chemotherapy Protocols (administration & dosage, therapeutic use)
  • Combined Modality Therapy (methods)
  • Cyclophosphamide (administration & dosage)
  • Disease-Free Survival
  • Doxorubicin (administration & dosage)
  • Female
  • Humans
  • Lymphoma, B-Cell (drug therapy, radiotherapy)
  • Male
  • Middle Aged
  • Prednisone (administration & dosage)
  • Quality of Life
  • Remission Induction
  • Stomach Neoplasms (drug therapy, radiotherapy)
  • Time Factors
  • Vincristine (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: